A group of physicians from the departments of Human Physiology, Hematology, Psychology and Oncology at the Academic Hospital of the Free University of Brussels in Belgium teamed up to examine both the efficacy and safety of Ampligen as a treatment for Chronic Fatigue Immune Dysfunction (also known as Chronic Fatigue Syndrome).
The still experimental drug Ampligen, long in the news for showing extremely positive clinical test results in CFS patients since 1988, hasn’t appeared in the U.S. studies due to both problems with the Food and Drug Administration (FDA) as well as HEM Pharmaceuticals, the company that manufactures the drug.
According to preliminary reports, the aim of the study was “to evaluate the activity and safety of intravenous Ampligen” in patients who were very sick with CFS, referred to in Brussels as myalgic encephalomyelitis (ME).
The Brussels team treated 11 patients that met the CDC diagnostic criteria with 200-400 mgs of intravenous Ampligen, depending on body weight, twice a week. The patients receiving the medication were examined twice weekly using rigorous assessments to determine the efficacy and safety of the drug. Physicians observed the degree of debilitation, aerobic capacity function, subjective symptom scales, physical exams, and other safety assessments.
At 24 weeks, the team reported that all 11 patients experienced improvement in debilitation including significant improvement of symptoms, extended stamina, and aerobic ability. Most importantly in terms of future use of Ampligen was the absence of drug toxicity or any other side effects.
The Brussels physicians feel that these results show that Ampligen is not only safe and well tolerated, but is a promising treatment for Chronic Fatigue Immune Dysfunction Syndrome.